ADMS
Adamas Pharmaceuticals
ADMS
ADMS
Delisted
ADMS was delisted on the 23rd of November, 2021.
63 hedge funds and large institutions have $148M invested in Adamas Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 20 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
6% less capital invested
Capital invested by funds: $157M → $148M (-$9.64M)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
Holders
63
Holding in Top 10
2
Calls
$819K
Puts
$23K
Top Buyers
| 1 | +$5.99M | |
| 2 | +$1.15M | |
| 3 | +$869K | |
| 4 |
ACM
Altium Capital Management
New York
|
+$759K |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$737K |
Top Sellers
| 1 | -$5.41M | |
| 2 | -$1.23M | |
| 3 | -$1.21M | |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.03M |
| 5 |
Two Sigma Advisers
New York
|
-$877K |
